Efficacy Assessment and Monitoring of Subcutaneous Infliximab Levels.

Real World Data on Vedolizumab Concentration and Outcomes in Inflammatory Bowel Disease (IBD) Patients Switching From Intravenous (IV) to Subcutaneous (SC) Vedolizumab in University Hospital Center Osijek

NCT05504915 ·Status: COMPLETED

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

NCT02438410 ·Status: COMPLETED

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

NCT06113913 ·Status: RECRUITING ·Phase: PHASE4

Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission

NCT03841942 ·Status: TERMINATED ·Phase: NA

Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease

NCT06381518 ·Status: COMPLETED ·Phase: NA

A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease

NCT02904590 ·Status: COMPLETED

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of the Effectiveness of Kits Promonitor-IFX/ADL and Promonitor-Anti-IFX/ADL in Patients With IBD

NCT06666569 ·Status: COMPLETED

Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab

NCT02453776 ·Status: COMPLETED ·Phase: PHASE4

Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk

NCT02193464 ·Status: RECRUITING

IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®

NCT05722353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy

NCT03359642 ·Status: COMPLETED ·Phase: NA

Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.

NCT05291039 ·Status: COMPLETED ·Phase: NA

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

NCT03765450 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis

NCT01408810 ·Status: COMPLETED ·Phase: PHASE4

Inflammatory Bowel Disease Research Registry

NCT00574028 ·Status: COMPLETED

Role of 90K/Mac-2 BP as an Indicator of Early Response to Infliximab Therapy in IBD Patients

NCT05960162 ·Status: UNKNOWN

A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease

NCT02505568 ·Status: COMPLETED ·Phase: PHASE3

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

NCT05197049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Biomarkers to Predict and Monitor Response to Infliximab

NCT04655729 ·Status: UNKNOWN

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

NCT05377580 ·Status: COMPLETED ·Phase: PHASE2

Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases

NCT02508012 ·Status: COMPLETED ·Phase: NA

GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )

NCT02994836 ·Status: COMPLETED ·Phase: PHASE4

Immunological Characteristics of Preclinical IBD

NCT05698745 ·Status: RECRUITING

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

NCT03945019 ·Status: COMPLETED ·Phase: PHASE3